Shop By
Catalog No.
Product Name
Application
Product Information
Product Citation
-
Antagonist of IAPs inhibitor
LCL161 is an orally bioavailable second mitochondrial-derived activator of caspases (SMAC) mimetic and inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, with potential antineoplastic activity.- Han-Hee Park, .et al. , Mol Cancer, 2021, Aug 21;20(1):107 PMID: 34419074
- Se-Yeon Park, .et al. , Cell Death & Disease, 2020, 11:744 PMID: 32917855
- J Chen, .et al. , JBC, 2019, June PMID: 31217278
- Choi SW, .et al. , Mol Cell, 2018, Jun 7;70(5):920-935.e7 PMID: 29883609
- Han-Hee Park, .et al. , Exp Mol Med, 2018, Sep; 50(9): 125 PMID: 30237400
- Gi-Bang Koo, .et al. , Cell Res, 2015, Jun; 25(6): 707-725 PMID: 25952668
- Kim SK, .et al. , J Invest Dermatol, 2015, Aug;135(8):2021-2030 PMID: 25748555
-
XIAP/cIAP1 antagonist
Birinapant, also known as TL32711, is a synthetic small molecule and peptido mimetic of second mitochondrial-derived activator of caspases (SMAC) and inhibitor of IAP (Inhibitor of Apoptosis Protein) family proteins, with potential antineoplastic activity. -
cIAP-2 antagonist
SM-164 is a potent cell-permeable and bivalent Smac mimetic which bind to a XIAP protein with a Ki value of 0.56 nM, and binds to cIAP-1 and cIAP-2 proteins with Ki values of 0.31 and 1.1 nM, respectively.- Hanna Yuk, .et al. , Antioxidants (Basel), 2021, Aug 25;10(9):1347 PMID: 34572979
- Caroline Moerke, .et al. , Cell Death Differ, 2018, Nov 15 PMID: 30442947
